| monrd0002 | |
| Medals oligonucleic drug ID | monrd0002 |
| ATC Classification | - |
| Product Name | aganirsen |
| Synonims | GS101 |
| Country | France |
| Company | Les Laboratoires CTRS |
| phase | II/III |
| Type | Antisense |
| Adaptation Diseases | inhibition of corneal neovascularisation, a major risk factor of corneal graft rejection |
| Target Molecule | insulin receptor substrate-1 (IRS1) |
| Remarks | Aganirsen is an antisense oligonucleotide ophthalmic solution that inhibits the function of insulin receptor IRS1. In Phase II study, inhibition of corneal neovascularization was confirmed. Double mask, randomization, placebo-controlled Phase III trials at multiple locations examined clinical benefits for vision, QoL, and the need for transplantation. The trial showed significant inhibition of corneal angiogenesis in patients with keratitis, a significant reduction in transplantation need in viral keratitis and central angiogenic patients. The safety of topical application was also confirmed. |
| Nucleic Acid Sequence | - |
| Source | https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-005388-33/DE, https://www.clinicaltrialsregister.eu/ctr-search/trial/2004-005015-29/DE, https://www.clinicaltrialsregister.eu/ctr-search/trial/2004-005015-29/results, http://www.ncbi.nlm.nih.gov/pubmed/19643487, https://www.ncbi.nlm.nih.gov/pubmed/24811963, http://www.genesignal.com/GS-101_Aganirsen_Clinical_Tr.32.0.html |
| DrugBank | - |
| TargetProtein - UniProt | P35568 |
| TargetProtein - PDB | 1IRS, 1QQG |